Researchers from the University of Goteborg, Lund University, Roche Diagnostics International and the Barcelonaβeta Brain Research Center participate in the project ‘Fully automated plasma assays as screening tests for Alzheimer-related amyloid beta (Aβ) pathology’, funded by the Alzheimer’s Drug Discovery Foundation.
The aim of the research project is to develop a screening/triage algorithm based on well-validated blood tests for amyloid pathology that could be implemented in primary care settings and used for the effective identification of amyloid-positive individuals. Researchers hypothesise that the novel fully automated plasma Aβ tests will be able to characterize the amyloid status of cognitively preserved participants and patients with cognitive complaints in primary care.
A blood test for cerebral β-amyloidosis would make it possible to expand the patient base that could be considered for inclusion in clinical trials against Alzheimer’s disease considerably and reduce screen failure rates. This approach will facilitate Alzheimer’s disease drug development and prepare effective clinical pathways for the advent of disease-modifying therapies targeted against amyloid pathology.
This new assay will be validated in participants from cohort studies at BBRC, the Swedish cohort BIOFINDER and in persons coming from various Swedish primary care units.